May 20, 2026 Flerie’s portfolio company Prokarium presents positive interim data from clinical study in bladder cancer Read more
April 21, 2026 Flerie’s portfolio company Mendus advances clinical program with first patient enrolled in phase 1b trial Read more
March 10, 2026 Flerie’s portfolio company Lipum selected for EUR 8 million Horizon Europe grant Read more
February 27, 2026 Flerie’s portfolio company Xspray Pharma appoints Blake Leitch as CEO and resubmits application for market approval of Dasynoc® to the FDA Read more
February 11, 2026 Flerie’s portfolio company Microbiotica reports positive Phase 1b data for MB310 in patients with ulcerative colitis Read more
January 20, 2026 Flerie’s portfolio company Chromafora acquires Montrose Environmental Group Denmark Read more
January 9, 2026 Flerie’s portfolio company KAHR Bio presents strong survival data from Phase II trial with DSP107 and secures USD 22 million in equity funding Read more
